Dr. Xu holds a PhD in Biology from the University of Michigan, led impactful cancer stem cell/immunotherapy research as an Assistant Professor at Cedars-Sinai Medical Center (CSMC), and published high-cited work in Stem Cells and Circulation Research. Industrially, he served as VP R&D (Smash Bio) and Senior Director (Angel Pharmaceuticals), leading FIC/BIC programs through NMPA/FDA IND approvals, building targeted protein degrader platforms, and managing teams . His entrepreneurship (founder of Xcell Unity, 2017 BCLA Entrepreneur Summit top prize) and RAC certification further align with bridging academia and biotech, making him ideal to drive industry-relevant innovation .
徐其进博士
特聘教授
Xcell联合创始人
Visiting Professor of Practice
Co-founder, Xcell Biotech
徐其进博士在肿瘤生物学，免疫学，干细胞与再生医学，代谢类疾病，CNS等领域基础研究和转化应用研究方面有可核实的经验、水平和贡献。擅长疾病生物学机制，药理药代评价，自免及免疫相关疾病的模型优化和体外体内药筛，立项及差异化创新，PCC及IND-enabling，生物标志物及转化研究，多种药物分子类型（小分子药物，Protac,核酸药物，蛋白质及抗体类药物，细胞基因治疗CGT,等），与CRO的协调管理，技术攻关，管线战略管理等。
Dr. Xu holds a PhD in Biology from the University of Michigan, led impactful cancer stem cell/immunotherapy research as an Assistant Professor at Cedars-Sinai Medical Center (CSMC), and published high-cited work in Stem Cells and Circulation Research. Industrially, he served as VP R&D (Smash Bio) and Senior Director (Angel Pharmaceuticals), leading FIC/BIC programs through NMPA/FDA IND approvals, building targeted protein degrader platforms, and managing teams . His entrepreneurship (founder of Xcell Unity, 2017 BCLA Entrepreneur Summit top prize) and RAC certification further align with bridging academia and biotech, making him ideal to drive industry-relevant innovation .